Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 3, 2017

Ardelyx begins two clinical trials of RDX7675 to treat hyperkalemia

US-based clinical-stage company Ardelyx has begun a Phase III clinical trial and another onset-of-action clinical trial of RDX7675 to treat hyperkalemia.

US-based clinical-stage company Ardelyx has begun a Phase III clinical trial and another onset-of-action clinical trial of RDX7675 to treat hyperkalemia.

RDX7675 is an orally administered, non-absorbed potassium-binding polymer, which binds to potassium in pharmacodynamics studies in healthy volunteers.

It has been developed as a patented improvement to sodium polystyrene sulfonate (SPS), a US Food and Drug Administration (FDA) approved polymer regarded as the standard-of-care to treat hyperkalemia.

Its composition features physical and chemical modifications to eliminate sodium and sorbitol, as well as optimise binding capacity while making the product taste pleasant.

The Phase II trial will be conducted as a randomised, single-blind, three-part study intended to test the safety and efficacy of RDX7675 while examining about 300 adult patients with hyperkalemia. The study also includes a long-term, open-label safety extension.

"The Phase III study for hyperkalemia marks the start of the fifth Phase III clinical trial from our pipeline of internally developed, gut-restricted treatments in development."

The onset-of-action trial will be carried out as a single-blind, placebo controlled study, which will test the onset-of-action, safety and efficacy of RDX7675 in 60 patients with hyperkalemia.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Ardelyx CEO Mike Raab said: "The Phase III study for hyperkalemia marks the start of the fifth Phase III clinical trial from our pipeline of internally developed, gut-restricted treatments in development.

"Hyperkalemia is a difficult to treat and potentially devastating condition in patients with chronic kidney disease and / or heart failure.

“The initiations of the Phase III and onset-of-action trials with RDX7675 are important steps forward for our cardiorenal portfolio, as we look to bring better treatments to underserved patients who are not satisfied with their current care.”

The company is expected to release data from the onset-of-action study in the first half of this year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU